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Background: Using 30-day operative mortality reported with lower extremity bypass (LEB) in preoperative decision
making may underestimate the actual death rate encountered before patients have truly recovered from surgery, especially
in elderly, debilitated patients with significant tissue loss. Therefore, we examined preoperative, patient-level risk factors
that predict survival within the first year following LEB.
Methods: Using our regional quality improvement initiative in 11 hospitals in Northern New England, we studied 2306
LEB procedures performed in 2031 patients between January 2003 and December 2007. Sixty surgeons contributed to
our database, and over 100 demographic and clinical variables were abstracted by trained researchers. Cox proportional
hazards models were used to generate hazard ratios (HR) and surrounding 95% confidence intervals (CI) for our
combined outcome measure of death occurring within the first year postoperatively.
Results: We found that within our cohort of 2306 bypass procedures, 11% of patients died within 1 year of surgery (2%
prior to discharge, 9% prior to 1-year follow-up). We identified six preoperative patient characteristics associated with
higher risk of death in multivariate analysis: congestive heart failure (HR 1.3, 95% CI 1.0-1.8), diabetes (HR 1.5, 95%
CI 1.1-2.1), critical limb ischemia (CLI) (HR 1.7, 95% CI 1.3-2.4), lack of single-segment saphenous vein (HR 1.9, 95%
CI 1.5-2/5), age over 80 (HR 2.0, 95% CI 1.5-2.7), dialysis dependence (HR 2.7, 95% CI 1.9-3.6), and emergent nature
of the procedure (HR 3.4, 95% CI 1.7-6.8). While patients with no risk factors had 1-year death rates that were less than
5%: patients with three or more risk factors had a 28% chance of dying before 1 year postoperatively. When we compared
risk-adjusted survival across centers, we found that one center in our region performed significantly better than expected
(observed-to-expected outcome ratio 0.7, 95% CI 0.6-0.9, P  .04).
Conclusions: Preoperative risk factors allow surgeons to predict survival in the first year following LEB, and to more precisely
inform patients about their operative risk with LEB. Additionally, our model facilitates benchmarking comparison of
risk-adjusted outcomes across our region. We believe quality improvement measures such as these will allow surgeons to
identify best practices and thereby improve outcomes with LEB across centers. (J Vasc Surg 2010;51:71-9.)Although lower extremity bypass surgery (LEB) pro-
vides durable and effective treatment for peripheral arterial
disease (PAD), significant morbidity and mortality are en-
countered when elderly, medically complex patients are
subject to these operations.1 Patients must not only survive
the first 30 days after surgery; theymust live long enough to
heal their surgical wounds, rehabilitate from their hospital-
ization, restore their tissue loss, and regain their quality of
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doi:10.1016/j.jvs.2009.07.123life. Patients often do not reach several of these milestones
by 30 days postoperatively.2-4 However, 30-day mortality
remains a common endpoint reported in studies of mortal-
ity following LEB.1,5 Optimal patient selection, we rea-
soned, would be to operate on patients who would survive
1 year after surgery.
Therefore, we sought to improve patient selection by
developing a risk prediction model for survival within the
first year following LEB. Along with our prior reports
examining risk factors associated with functional outcomes
following bypass surgery,6,7 we believe this work will in-
form patients and surgeons not only about the risks of
death in the short-term perioperative period but also in the
recovery period.
METHODS
Subjects and databases. We utilized data collected
prospectively by the Vascular Study Group of Northern
New England (VSGNNE), a regional cooperative quality
improvement initiative developed by 11 community and
academic centers in 2002 to study regional outcomes in
vascular surgery. Further details on this registry have been
published previously,8 and others are available at vsgnne.org.
We included only patients who underwent open in-
frainguinal bypass procedures. Bypasses inflow could be
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knee or below-knee, popliteal, tibial, or pedal vessels. Pa-
tients with concomitant endovascular procedures (such as
an iliac stent done at the time of bypass surgery) were
included in the analysis as well. Bypass procedures could be
performed in an in situ fashion, with reversed vein, with
vein cuffs or adjuncts, or with prosthetic conduit. We
limited this analysis to patients with occlusive disease and
eliminated all patients undergoing lower extremity bypass
for aneurysmal disease, such as popliteal aneurysms.
Definitions and outcome measures. Our unit of
analysis was the patient, and our main outcome measure
was death following surgery. Between January 1, 2003, and
December 31, 2007, we identified 2036 patients in our
database that underwent 2301 bypass procedures; several
patients underwent more than one bypass procedure. In
these cases, we studied only the initial bypass procedure. A
bypass graft revision on the same leg was considered a
revision of the index bypass, whereas a new bypass on an
ipsilateral leg was examined as a new and distinct bypass.
While graft occlusions were considered on a per-graft basis,
major amputation was censored on each extremity after the
occurrence of a major amputation on that extremity. All
bypasses were performed for occlusive disease; we elimi-
nated from our analysis any bypass performed for aneurys-
mal disease, such as popliteal aneurysm.
Patients were evaluated for pre-existing medical co-
morbidities, and these data were prospectively entered into
our registry by specifically trained surgeons, nurses, or
clinical data abstractors. Over 70 clinical and demographic
variables were collected on each patient, and these have
been described in our prior work.8,9 These demographic
data and the incidence of patient-level comorbidities are
outlined in Table I.
Our main outcome measure was death, occurring
within 1 year following surgery. We used life table analysis
given that not all follow-up data were obtained at exactly 1
year. A current version of the Social Security Death Index as
well as 1-year follow-up data obtained as part of VSGNNE
were used to confirm the survival status of all patients
during the first year after bypass surgery. Graft patency and
major amputation rates were determined at two stages.
First, we measured patency and amputation rates at the
time of discharge and again at 1 year postoperatively. Graft
patency, determined by duplex or angiographic evaluation,
was categorized as primary, assisted-primary, and second-
ary. Major amputation was defined as above-knee amputa-
tion or below-knee amputation. This outcome was assessed
both at discharge and again at 1-year follow-up. Trans-
metatarsal amputations and toe amputations were not in-
cluded in this outcome measure, as they do not imply
failure of limb salvage. A procedure was defined as urgent if
it was performed within 12 to 72 hours of nonelective
patient admission and emergent if performed within 12
hours of nonelective patient admission.
Development and validation of our risk model and
benchmarks. In our univariate analysis, we made compar-
isons of each variable with our main outcome measure.Tests of significance were established with chi-squared and
Fisher’s exact tests, as well as Kaplan-Meier survival curves
and log-rank tests. Risk factors found by univariate analysis
to be associated with a P value of0.1 were then used in a
multivariate Cox proportional hazards model. This model
was then used to calculate hazard ratios (HR) and 95%
confidence intervals (CI) for the ability to survive 1 year
after surgery. Backward stepwise regression was utilized to
construct the model using the variables described above.
To examine the validity of our risk prediction model,
we constructed our model from the data obtained between
2003 and 2006. We then applied the risk model to data
acquired from the VSG sites in 2007.Model discrimination
was then evaluated by comparing the rates of death across
differing groups of patient risk; the significance of these
differences was evaluated using log-rank tests. Further, we
used concordance testing to evaluate the performance of
our Cox proportional hazards model.10,11
Finally, to establish benchmarks and comparisons of
performance, we compared results across centers, based on
the characteristics of the patients treated at each center.
Using our model, we predicted a 1-year risk of death for
each patient, based on that patient’s individual risk factor
profile. Aggregating by center, the predictive ability of each
model was then evaluated by generating an observed-to-
expected outcome ratio (O/E ratio) across the range of risk
identified. These O/E ratios allow comparison of the actual
results at each center with the predicted results at each
center. Differences between observed and expected values
were compared using t tests, with and without corrections
for multiple testing (Bonferroni’s correction11).
All analyses were performed using Microsoft Excel
(Redmond,Wash) and STATA (College Station, Tex). The
Institutional Review Board at Dartmouth Medical School
reviewed and approved our study protocol.
RESULTS
Patient characteristics. Between January 1, 2003,
and December 31, 2007, 2036 patients underwent LEB in
Northern New England at one of the 11 centers participat-
ing in our registry. Patients were most commonly male
(67%), mean age was 73 years, and nearly all were Cauca-
sian. Nearly all patients had a history of either prior or
current smoking (82%). About half of the patients had a
history of diabetes, 40% had coronary disease, and nearly
one-third had a history of chronic obstructive pulmonary
disease (COPD). Indication for surgery was claudication in
25% of patients, while 75% of patients had critical limb
ischemia (CLI). Further details about the characteristics of
the cohort used are available in Table I. While our cohort
represents more than 2000 bypass procedures, no one
center or surgeon was adequately powered to measure
volume effects at the hospital (range, 16-198 bypasses per
year, mean, 69 bypasses per center per year) or surgeon
(range, 1-67 bypasses per year, mean, 16 bypasses per
surgeon per year) level. Therefore, volume strata are not
used in our analyses.
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Variable
Total (%)
(Total n  2,036
patients)
Percent died at 1
year if variable not
present
Percent died at 1
year if variable
present P value
Male gender 67% 11% 10% .9
Right side 50% 11% 10% .821
Non-white race 2% 11% 12% .754
Not living home preoperatively 5% 10% 27% .0001
Not independently ambulatory preoperatively 24% 9% 18% .0001
Age
Age 40 (referent) 1% 11% 0%
Age 40-50 6% 22% 4%
Age 50-60 19% 12% 5%
Age 60-70 27% 12% 7%
Age 70-80 30% 9% 14%
Age 80-90 15% 9% 22%
Age 90-100 1% 10% 29% .001 (across groups)
Smoking (prior or current) 82% 15% 9% .001
COPD 29% 9% 14% .0001
Diabetes (all diabetics) 53% 7% 13% .0001
Non-insulin-dependent diabetics (referent) 26% 9% 14%
Insulin-dependent diabetics 21% 9% 14% .002 (across groups)
Coronary disease 40% 10% 13% .04
Congestive heart failure 18% 8% 20% .0001
Tissue loss/rest pain 75% 4% 13% .0001
Concomitant ipsilateral proximal angioplasty/stent 3% 11% 9% .685
Preoperative medication regimen
Anti-platelet agent use 71% 12% 11% .204
Preoperative statin use 59% 12% 9% .07
Preoperative beta blocker use
No beta blocker (referent) 18% 11% 11%
Perioperative beta blocker 22% 12% 8%
Chronic beta blocker 58% 9% 11% .02 (across groups)
Operative characteristics
External iliac origin 2% 11% 9% .577
Common femoral origin 70% 11% 10% .315
Profunda origin 3% 10% 12% .793
Superficial femoral artery origin 16% 10% 12% .404
Above-knee popliteal origin 4% 11% 11% .931
Below-knee popliteal origin 5% 10% 14% .263
Superficial femoral artery recipient 1% 11% 9% .779
Above-knee popliteal recipient 26% 12% 9% .1
Below-knee popliteal recipient 31% 11% 11% .804
Tibio peroneal trunk recipient 3% 11% 9% .542
Anterior tibial recipient 10% 11% 14% .116
Posterior tibial recipient 10% 11% 10% .502
Peroneal recipient 7% 10% 14% .216
Posterior tibial artery at ankle recipient 4% 10% 14% .299
Dorsalis pedis recipient 6% 10% 13% .231
Tarsal recipient 1% 10% 12% .807
Anesthesia type
General anesthesia 75% 11% 10%
Epidural 8% 10% 10%
Spinal 16% 10% 12% .416 (across groups)
Conduit
Dacron 2% 10% 17% .174
PTFE 23% 10% 14% .019
Other non-autologous conduit 3% 10% 17% .168
One vein segment 67% 14% 9% .0001
Two vein segments 6% 10% 17% .044
Completion study (duplex or arteriogram) 68% 9% 11% .378
Postoperative complications
Superficial wound infection 5% 10% 12% .499
Return to OR (any reason) 14% 10% 20% .0001
Return to OR (thrombosis) 3% 16% 23% .139
, poly
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percent of patients had a bypass that originated from the
common femoral artery, and 74% of bypasses were anasta-
mosed to a below-knee target vessel. Most bypasses (73%)
used native vein as a conduit, and 32%were performed in an
in situ fashion. A completion arteriogram or duplex study
was obtained in 68% of bypasses. As we have reported
previously with this dataset, graft patency rates were better
in claudicants as compared with patients with CLI (claudi-
cant primary and secondary patency) 79% (95% CI 77%-
81%) and 87% (95% CI 85%-92%), critical ischemia primary
and secondary patency 73% (95% CI 70%-75%) and 81%
(95% CI 79%-83%), log-rank between groups P  .0001
for all comparisons). Patients with critical ischemia had an
85% limb salvage rate at 1 year.
Univariate and multivariate predictors of survival.
As expected in our cohort, rates of survival at 1 year were
higher in patients with claudication compared with CLI
(97% [95% CI 95%-98%] versus 89% [95% CI 86%-91%],
P  .0001, Fig 1). In univariate comparisons, we found
that several variables were associated with increased risk of
death at 1 year (Table I). Not surprisingly, these included
the presence of heart disease, renal failure, and evidence of
CLI.
By multivariate analysis, there were seven preoperative
risk factors associated with death at 1 year (Table II). These
were the presence of congestive heart failure, diabetes,
presence of CLI, lack of single-segment saphenous vein,
age over 80 years, dialysis dependence, and emergent na-
Table I. Continued.
Variable
Total (%
(Total n 
patient
Discharge variables
Home 68%
Rehabilitation facility 17%
Nursing home 12%
Ambulating independently at discharge 48%
Death at discharge 2%
COPD, Chronic obstructive pulmonary disease; OR, operating room; PTFE
Value shown is for diet-controlled diabetes mellitus.
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Fig 1. Survival following LEB, by indication.ture of the procedure. The effect of these risk factors wasadditive. For example, the risk of death at 1 year was
minimal (3%) in those with no risk factors but reached
nearly 30% in those patients with three or more risk factors
(Figs 2 and 3).
Finally, to examine the validity of our risk prediction
model, we constructed our risk model from the data obtained
between 2003 and 2006 and applied the risk model to the
data acquired from the VSG sites in 2007. We found that our
Percent died at 1
year if variable not
present
Percent died at 1
year if variable
present P value
5% 23% .0001
9% 17% .0001
9% 18% .0001
5% 14% .0001
tetrafluoroethylene.
Table II. Multivariate Cox proportional hazards model
used to predict amputation or graft occlusion at 1 year
following lower extremity bypass
Preoperative characteristic
Hazard
ratio
95% confidence
interval P value
Congestive heart failure 1.3 1.0-1.8 0.05
Diabetes
Diet controlled 1.4 0.8-2.5 0.214
Oral hypoglycemic 1.5 1.1-2.1 0.021
Insulin 1.2 0.8-1.6 0.421
Critical limb ischemia 1.7 1.3-2.4 0.001
No single-segment GSV 1.9 1.5-2.5 0.0001
Age over 80 2.0 1.5-2.7 0.0001
Dialysis 2.7 1.9-3.6 0.0001
Emergent procedure 3.4 1.7-6.8 0.0001
GSV, Great saphenous vein.
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Fig 2. Survival following LEB, by number of risk factors.)
2,036
s)model performed well in discriminating risk (concordance
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with no risk factors had excellent survival at 1 year, and
similarly patients with three or more risk factors had poorer
survival. As with our main cohort, differences between these
groups were statistically significant.
Benchmarking using our risk prediction model.
Risk prediction models allow benchmarking and facilitate
comparison of risk-adjusted outcomes across centers as part
of quality improvement efforts. To this end, we used our
risk prediction model to calculate expected death rates
across centers and compared observed results with the
expected results using O/E ratios.
Predicted risks of death varied from 2% at our lowest-risk
centers to 23% at the highest-risk center (Fig 4). When we
compared observed and expected risks, we found that most
centers performed nearly as expected. However, one center
(center 2) had a predicted 1-year death rate of 4%but an actual
death rate of 10% (0/E ratio 0.7, 95% CI 0.6-0.9, P .04) –
this center performed significantly worse than expected. Cen-
ter 9, however, had an expected death rate of 23% but
observed only a 4% death rate during the study period, a
difference that was significantly better than expected. Several
other centers had results that were slightly better or worse
than predicted (O/E ratios of less or more than 1), but none
of these differences was statistically significant.
It is important to note that in analyses correcting for the
possibility of chance in comparisons across centers (a Bonfer-
roni correction), we found that to demonstrate statistically
significant differences between observed and expected results,
the level of significance would require a P value of P .007.
No centers in our analyses achieved this level of significance.
Finally, as stated previously, a small number of event rates
coupled with relatively small samples across centers and sur-
geons precluded meaningful volume analyses.
DISCUSSION
In our regional analysis of patients undergoing LEB,
we found that eight risk factors (age over 80 years, diabetes,
dialysis dependence, presence of CLI, inadequate single-
segment saphenous vein, congestive heart failure, and
emergent nature of the procedure) allow surgeons to predict
Fig 3. Kaplan-Meier survival curves following LEB, by number of
risk factors.which patients are at the highest risk for death within the firstyear following surgery. Additionally, this model allowed us to
establish benchmarks for performance and compare risk-ad-
justed long-term outcomes within our region.
By establishing benchmarks and allowing comparison
of risk-adjusted outcomes, our model facilitates quality
improvement initiatives such as the VSGNNE. Within this
collaborative, surgeons can compare risk-adjusted out-
comes and determine which centers have the best results.
By studying those centers, surgeons may be able to identify
processes of care that contribute toward the best outcomes.
Then, by widely implementing these processes of care, we
hope to improve our results across the region. This model
has been used effectively in cardiac surgery,12,13 myocardial
infarction care,14,15 in the treatment of pulmonary dis-
ease,16 and cancer.17 In addition to these ongoing efforts in
quality improvement in LEB surgery, we are applying sim-
ilar strategies in improving results after carotid endarterec-
tomy in our region.9
But in determining the risk-adjusted outcomes after
LEB, which is the best parameter by which to measure
success? Is the best center the one with the lowest operative
mortality? The best long-term survival? The highest limb
salvage rate? The best ambulation rate year after surgery?
The answer to this question is both important and contro-
versial. Most investigators have used amputation-free sur-
vival as the central measure of the efficacy of lower extrem-
ity revascularization for CLI. As an outcome, this variable
makes intuitive sense. Few surgeons consider the operation
a success if the patient’s graft occludes, they undergo an
amputation, or die within the first year after surgery. There-
fore, successful surgeons must choose to operate on only
those patients who will live for at least 1 year after surgery
and only those patients who will not suffer amputation or
graft occlusion within the first year after their bypass.
However, developing a risk prediction model for
amputation-free survival is difficult, since the risk factors that
predict death are not likely the same risk factors that predict
amputation. In recent work, we found that while the two
outcomes (death and amputation) share some similar risk
factors (presence of critical ischemia, advanced age, diabetes,
dialysis dependence, and lack of acceptable saphenous vein)
(Fig 5).However, survival is further influenced by physiologic
factors (such as congestive heart failure and emergent proce-
dures), while amputation is more strongly influenced by func-
tional status, technical aspects of the operation, and patient
age.Unfortunately, creating amodel that successfully predicts
both of these outcomes diminishes the ability to predict either
death or amputation alone. Therefore, while amputation-free
survival may accurately reflect the overall effectiveness of LEB
surgery, it is difficult to precisely predict which patients are at
the highest risk for this outcome.
How will surgeons use our model to predict survival
after LEB? We believe patients and surgeons can use this
risk model not only to guide their expectation for 1-year
mortality risk with bypass surgery but also to weigh the risks
and benefits when considering surgery or endovascular
intervention. Patients with only one or two risk factors have
little if any chance of death within the first year after
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nearly 30% chance of not surviving the first year after
surgery. Especially in this latter group of patients, given the
morbidity and mortality incurred with bypass surgery, we
suspect many surgeons would give consideration to using
endovascular interventions, even in less-than-ideal set-
tings.18 Althoughmany believe that an “endovascular first”
strategy should be applied to all patients,18-20 practice
patterns vary significantly, and best practices have yet to be
established with high-quality evidence. Few randomized
trials have directly compared the safety and efficacy of LEB
and endovascular interventions.19,21 In the absence of this
information, accurate prediction of outcome is critical to
such decision making. Application of our model to endo-
vascular interventions may also allow comparison between
open and endovascular methods, helping to refine decision
making between these two methods. Given expertise in
both open and endovascular realms, we believe it is incum-
bent upon vascular surgeons to lead the effort in this
comparative effectiveness research.
Our study has limitations. First, our endpoint in this
study addresses only one of the main questions necessary
for surgeons to ensure proper patient selection. As stated
above, surgeons must consider other outcomes of LEB
surgery, not just death. Surgeons must consider the func-
tional outcome of the procedure, such as the probability
that the patient will remain ambulatory after surgery and
whether or not the patient may experience complications
such as graft occlusion or amputation. Because different risk
factors dictate these outcomes, we modeled each outcome
separately, and this work has been reported previously, by our
group andothers.6,7,22-25 Second, our studydata are obtained
as part of a voluntary quality-improvement registry, and out-
comes are self-reported. While we cannot be certain that all
complications were included, for two reasons, we believe
our data are complete and accurate. First, in terms of
completeness, our database is audited biannually and com-
pared with discharge abstracts from our participating insti-
tutions. These audits8 have demonstrated a 99% accuracy of
our database in terms of inclusion of all bypass procedures
in our region. Second, in terms of accuracy, our results
share similar risk factors and effect size with other recent
studies that have examined risks of death following lower
extremity bypass surgery (Table III). One notable differ-
Table III. Recent studies examining risk factors for death
Author Year n, Study type Outcom
Schanzer et al22 2008 1,404 patients, multi-center
randomized trial
Survival
Feringa et al23 2007 1374 patients with PAD Long-te
morta
Owens et al3 2007 456 patients, single-center
series
Long-te
surviv
CAD, Coronary artery disease; CKD, chronic kidney disease; LDL, low-den
*Death not measured independently, measured as part of a combined outcence between these studies and our own is the lack ofsurvival benefit in our multivariate model with statins.
While many may consider these findings surprising, it is
important to note that our study was not a randomized
trial, and significant selection bias may exist in patients
treated or not treated with these medications. Our study
analyzed both claudicants and patients with CLI. While
many might argue that these groups are too different to
be truly comparable, we made a conscious decision to
focus on generalizability in designing our model, and
accordingly we included both claudicants and CLI. Ac-
cordingly, we were careful in designing our multivariate
model such that differences in these populations were
taken into account. And finally, while our model has
obvious strengths and weaknesses, it was designed in the
context of our regional quality improvement initiative.
This initiative represents our effort, as vascular surgeons,
to best design tools that will allow us to measure and
improve our results.
In conclusion, we identified several risk factors that
allow surgeons to predict which patients are at risk for poor
survival following LEB. Moreover, this model permits
benchmarking and comparison of results across hospitals,
key activities within our quality improvement initiative. By
comparing risk-adjusted results and identifying best prac-
tices, we hope to improve survival in patients undergoing of
LEB across our region.
AUTHOR CONTRIBUTIONS
Conception and design: PG, BN, JC
Analysis and interpretation: PG, BN, AS, DL
Data collection: PG, BN, AS, JE, AC, DS, DL, JC
Writing the article: PG, BN, DL, JC
Critical revision of the article: PG, BN, AS, JE, AC, DS,
DL, JC
Final approval of the article: PG, BN, AS, JE, AC, DS,
DL, JC
Statistical analysis: PG, BN, AS, DL, JC
Obtained funding: PG, JC
Overall responsibility: PG
REFERENCES
1. Nowygrod R, Egorova N, Greco G, et al. Trends, complications, and
wing lower extremity bypass
sure Survival rate
Risk factors for death at 1 year or
more*
ear 86% if on statin
81% if not on statin
*Statin use, age75, CAD, CKD
stage 4/5, tissue loss
75% limb salvage at 2
years
Statin therapy, LDL reduction,
cholesterol
5-year survival of 23%
if CKD stage 4
*Age, CKD Stage 4/5
poprotein; PAD, peripheral arterial disease.
easure.follo
e mea
at 1 y
rm
lity
rm
almortality in peripheral vascular surgery. J Vasc Surg 2006;43:205-16.
JOURNAL OF VASCULAR SURGERY
January 201078 Patterson2. ConteMS, BandykDF, Clowes AW,Moneta GL, Seely L, Lorenz TJ, et
al; PREVENT III Investigators. Results of PREVENT III: a multi-
center, randomized trial of edifoligide for the prevention of vein graft
failure in lower extremity bypass surgery. J Vasc Surg 2006;43:742-51;
discussion 51.
3. Owens CD, Ho KJ, Kim S, Schanzer A, Lin J, Matros E, et al.
Refinement of survival prediction in patients undergoing lower extrem-
ity bypass surgery: stratification by chronic kidney disease classification.
J Vasc Surg 2007;45:944-52.
4. Feinglass J, McCarthy WJ, Slavensky R, Manheim LM, Martin GJ.
Functional status and walking ability after lower extremity bypass graft-
ing or angioplasty for intermittent claudication: results from a prospec-
tive outcomes study. J Vasc Surg 2000;31:93-103.
5. Comerota AJ, Weaver FA, Hosking JD, Froehlich J, Folander H,
Sussman B, Rosenfield K. Results of a prospective, randomized trial of
surgery versus thrombolysis for occluded lower extremity bypass grafts.
Am J Surg 1996;172:105-12.
6. Goodney PP, Likosky DL, Cronenwett JL. Predicting amputation or
graft occlusion after lower extremity bypass. J Vasc Surg 2009;49:1431-
9.e1.
7. Goodney PP, Likosky DS, Cronenwett JL; Vascular Study Group of
Northern New England. Predicting ambulation status one year after
lower extremity bypass. J Vasc Surg 2009;49:1431-9.e1.
8. Cronenwett JL, Likosky DS, Russell MT, Eldrup-Jorgensen J, Stanley
AC, Nolan BW; the Vascular Study Group of Northern New England.
A regional registry for quality assurance and improvement: the Vascular
Study Group of Northern New England (VSGNNE). J Vasc Surg
2007;46:1093-101; discussion 101-2.
9. Goodney PP, Likosky DS, Cronenwett JL, Vascular Study Group of
Northern New England. Factors associated with stroke or death after
carotid endarterectomy in Northern New England. J Vasc Surg 2008;
48:1139-45.
10. Antolini L, Boracchi P, Biganzoli E. A time-dependent discrimination
index for survival data. Stat Med 2005;24:3927-44.
11. Handbook of Statistics, Volume 27: Epidemiology and Medical Statis-
tics. Rao CR, Miller JP, Rao DC, Eds. New York: Elsevier; 2008.
12. Nugent WC. Clinical applications of risk-assessment protocols in the
management of individual patients. Ann Thorac Surg 1997;64(6
Suppl):S68-72; discussion S80-2.
13. O’Connor GT, Birkmeyer JD, Dacey LJ, Quinton HB, Marrin CA,
Birkmeyer NJ, et al. Results of a regional study of modes of death
associated with coronary artery bypass grafting. Northern New England
Cardiovascular Disease Study Group. Ann Thorac Surg 1998;66:
1323-8.
14. HolmanWL, SansomM, Kiefe CI, Peterson ED, Hubbard SG, Delong
JF, Allman RM. Alabama coronary artery bypass grafting project: results
from phase II of a statewide quality improvement initiative. Ann Surg
2004;239:99-109.
fied for improvements in care.15. Scott IA, Eyeson-Annan ML, Huxley SL, West MJ. Optimising care of
acute myocardial infarction: results of a regional quality improvement
project. J Qual Clin Pract 2000;20:12-9.
16. O’Connor GT, Quinton HB, Kahn R, Robichaud P, Maddock J, Lever
T, et al; Northern New England Cystic Fibrosis Consortium. Case-mix
adjustment for evaluation of mortality in cystic fibrosis. Pediatr Pulmo-
nol 2002;33:99-105.
17. O’Grady MA, Gitelson E, Swaby RF, Goldstein LJ, Sein E, Keeley P, et
al. Development and implementation of a medical oncology quality
improvement tool for a regional community oncology network: the Fox
Chase Cancer Center Partners initiative. J Natl Compr Canc Netw
2007;5:875-82.
18. Nolan BW, Finalyson S, Tosteson A, Powell RJ, Cronenwett JL. The
treatment of disabling intermittent claudication in patients with super-
ficial femoral artery occlusive disease–decision analysis. J Vasc Surg
2007;45:1179-84.
19. AdamDJ, Beard JD, Cleveland T, Bell J, Bradbury AW, Forbes JF, et al;
BASIL trial participants. Bypass versus angioplasty in severe ischaemia of
the leg (BASIL): multicentre, randomised controlled trial [see com-
ment]. Lancet 2005;366:1925-34.
20. Hirsch AT. Treatment of peripheral arterial disease–extending “inter-
vention” to “therapeutic choice” [see comment]. N Engl J Med 2006;
354:1944-7.
21. McQuade K, Gable D, Hohman S, Pearl G, Theune B. Randomized
comparison of ePTFE/nitinol self-expanding stent graft vs prosthetic
femoral-popliteal bypass in the treatment of superficial femoral artery
occlusive disease. J Vasc Surg 2009;49:109-15.
22. Kalbaugh CA, Taylor SM, Cull DL, Blackhurst DW, Gray BH, Langan
EM 3rd, et al. Invasive treatment of chronic limb ischemia according to
the Lower Extremity Grading System (LEGS) score: a 6-month report.
J Vasc Surg 2004;39:1268-76.
23. Schanzer A, Mega J, Meadows J, Samson RH, Bandyk DF, Conte MS.
Risk stratification in critical limb ischemia: derivation and validation of
a model to predict amputation-free survival using multicenter surgical
outcomes data. J Vasc Surg 2008;48:1464-71.
24. Taylor SM, Cull DL, Kalbaugh CA, Cass AL, Harmon SA, Langan EM
3rd, Youkey JR. Critical analysis of clinical success after surgical bypass
for lower-extremity ischemic tissue loss using a standardized definition
combining multiple parameters: a new paradigm of outcomes assess-
ment. J Am Coll Surg 2007;204:831-8; discussion 838-9.
25. Taylor SM, Kalbaugh CA, Blackhurst DW, Cass AL, Trent EA, Langan
EM 3rd, Youkey JR. Determinants of functional outcome after revas-
cularization for critical limb ischemia: an analysis of 1000 consecutive
vascular interventions. J Vasc Surg 2006;44:747-55; discussion 755-6.Submitted May 22, 2009; accepted Jul 24, 2009.INVITED COMMENTARYRobert B. Patterson, MD, Providence, RI
This represents yet another carefully written report from the
data collected by the Vascular Study Group of Northern New
England (VSGNNE). They have begun the arduous and necessary
task of correlating preoperative risk factor assessment with postop-
erative outcome data, to help guide vascular surgeons in their
choice of therapy for patients with vascular disease. To date, they
have reported outcomes of carotid therapies and several aspects of
lower extremity revascularization.
Rather than using traditional 30-day mortality, the authors
acknowledge that recovery from intervention often spans several
weeks to months, and from a patient perspective one-year out-
comes have more relevance. This report serves two primary goals –
establishing preoperative predictors of success, and developing
benchmarks for hospitals, and eventually individual surgeons, to
identify practices and procedures that could be adopted or modi-The first goal leads them to their most controversial sugges-
tion: “Therefore, successful surgeons must select for operation
only those patients who will live for at least a year after surgery, and
only those patients who will not suffer amputation or graft occlu-
sion within the first year after their bypass.” As we encounter
increasingly aged and ill patients, quality of life as well as longevity
becomes a critical factor. Many patients, if afforded the option,
would prefer limb salvage to amputation if the recovery and rehab
times were similar. Perhaps if the authors were able to incorporate
their previously published risk factors for predicting independent
ambulation (age, preoperative ambulatory ability, independent living
status, critical limb ischemia) into their model, a combined quality/
quantity of life estimate could be reached. They acknowledge the
difficulty of this, but it is certainly a worthy long term goal.
The second goal of this study and of the VSGNNE is timely
and prescient. As Congress and the Administration wrestle with
